1
|
Muñoz J. Impact of the COVID-19 pandemic on mechanical ventilation cases and mortality rates in non-SARS-CoV-2 patients: A nationwide analysis in Spain. Heart Lung 2024; 68:154-159. [PMID: 39003961 DOI: 10.1016/j.hrtlng.2024.06.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2023] [Revised: 06/27/2024] [Accepted: 06/30/2024] [Indexed: 07/16/2024]
Abstract
BACKGROUND The COVID-19 pandemic has presented unprecedented challenges for healthcare systems globally, impacting critical care resources and patient outcomes. Understanding its multifaceted effects is crucial for future crisis response. OBJECTIVE Analyze the repercussions of the COVID-19 pandemic on mechanical ventilation cases and mortality among non-SARS-CoV-2 patients. METHODS A nationwide database encompassing all patients receiving mechanical ventilation in Spain was used to compare the number of cases and clinical outcomes during COVID-19 (March 2020 - December 2021) to pre-pandemic cases (May 2018 - February 2020). Univariate and multivariate analyses were employed. RESULTS COVID-19 significantly reduced access to ventilation for non-COVID-19 patients. A 16 % decrease (12,099 fewer patients) was observed during the pandemic compared to pre-pandemic times. This reduction affected all analyzed conditions except self-inflicted injuries, coinciding with a rise in overall mortality risk (34.5% vs 35.6 %, OR 1.09, 95 %CI 1.06-1.12). The increased mortality was consistent across diverse admission types, including cancer (37.1% vs. 41.5 %, OR 1.18, 95 %CI 1.09-1.29), hemorrhagic strokes (55.4% vs. 56.6 %, OR 1.07, 95 %CI 1.02-1.20), acute myocardial infarction (35.6% vs. 38 %, OR 1.11, 95 %CI 1.01-1.21), non-SARS-CoV-2 pneumonia (44.5% vs. 45.8 %, OR 1.12, 95 %CI 1.02-1.24), septic shock (54.7% vs. 56.3 %, OR 1.10, 95 %CI 1.06-1.15), and prolonged ventilation (≥96 h) (37% vs. 38.2 %, OR 1.10, 95 %CI 1.06-1.10). CONCLUSIONS The findings underscore the profound impact of the COVID-19 pandemic on critical care utilization and patient outcomes among non-SARS-CoV-2 patients. As healthcare systems strive to mitigate future crises, these insights emphasize adaptable strategies for equitable access to life-saving treatments.
Collapse
Affiliation(s)
- Javier Muñoz
- ICU. Hospital General Universitario "Gregorio Marañón". Madrid. Spain.
| |
Collapse
|
2
|
Garcia-Carretero R, Vazquez-Gomez O, Gil-Prieto R, Gil-de-Miguel A. Hospitalization burden and epidemiology of the COVID-19 pandemic in Spain (2020-2021). BMC Infect Dis 2023; 23:476. [PMID: 37464303 DOI: 10.1186/s12879-023-08454-y] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2023] [Accepted: 07/10/2023] [Indexed: 07/20/2023] Open
Abstract
BACKGROUND Spain had some of Europe's highest incidence and mortality rates for coronavirus disease 2019 (COVID-19). Here we describe the epidemiology and trends in hospitalizations, the number of critical patients, and deaths in Spain in 2020 and 2021. METHODS We performed a descriptive, retrospective, nationwide study using an administrative database, the Minimum Basic Data Set at Hospitalization, which includes 95-97% of discharge reports for patients hospitalized in Spain in 2020 and 2021. We analyzed the number of hospitalizations, admissions to intensive care units, and deaths and their geographic distribution across regions of Spain. RESULTS As of December 31, 2021, a total of 498,789 patients (1.04% of the entire Spanish population) had needed hospitalization. At least six waves of illness were identified. Men were more prone to hospitalization than women. The median age was 66. A total of 54,340 patients (10.9% of all hospitalizations) had been admitted to the intensive care unit. We identified 71,437 deaths (mortality rate of 14.3% among hospitalized patients). We also observed important differences among regions, with Madrid being the epicenter of hospitalizations and mortality. CONCLUSIONS We analyzed Spain's response to COVID-19 and describe here its experiences during the pandemic in terms of hospitalizations, critical illness, and deaths. This research highlights changes over several months and waves and the importance of factors such as vaccination, the predominant variant of the virus, and public health interventions in the rise and fall of the outbreaks.
Collapse
Affiliation(s)
- Rafael Garcia-Carretero
- Department of Internal Medicine, Mostoles University Hospital, Rey Juan Carlos University, Madrid, Spain.
| | - Oscar Vazquez-Gomez
- Department of Internal Medicine, Mostoles University Hospital, Rey Juan Carlos University, Madrid, Spain
| | - Ruth Gil-Prieto
- Department of Preventive Medicine and Public Health, Rey Juan Carlos University, Madrid, Spain
| | - Angel Gil-de-Miguel
- Department of Preventive Medicine and Public Health, Rey Juan Carlos University, Madrid, Spain
| |
Collapse
|
3
|
Corcuera-Munguia M, Gil-Prieto R, Garcia-Carretero R, Gil-de-Miguel A. Hospitalization Burden Related to Herpes Zoster Infection in Spain (2016-2019). Infect Dis Ther 2023; 12:143-156. [PMID: 36348228 PMCID: PMC9868224 DOI: 10.1007/s40121-022-00717-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2022] [Accepted: 10/14/2022] [Indexed: 11/10/2022] Open
Abstract
INTRODUCTION Herpes zoster (HZ) and its complications still represent a significant burden for patients and health care systems. In Spain, vaccination is progressively being introduced and recommended for patients between 65 and 80 years old and patients > 18 years of age suffering from certain immunosuppression conditions. The aim of this study is to estimate the number of hospital admissions related to HZ from 2016 to 2019 in Spain. METHODS Data were collected from the Minimum Basic DataSet (MBDS) and codified according to the Spanish version of the 10th International Classification of Disease (ICD-10-CM codes B02-B02.9). Among others, variables such as sex, age and presence of complications were included. RESULTS A total of 27,642 hospitalizations were identified (90% in patients > 50 and 45.8% in patients > 80). Women represented 51.2% of the patients, and 59.9% of patients presented complications related to HZ. The hospitalization rate was 17.74, the mortality rate was 1.2, and the case fatality rate was 6.75%. All rates were significantly higher with age, among men and in complicated HZ. Immunosuppression status for which vaccination had been recommended represented 22.7% of the total cases, affecting mostly individuals > 65 and causing more deaths in those > 80 years. The estimated annual cost of hospitalization for herpes zoster was €35,738,285, and the mean cost per patient was €5172. CONCLUSION The hospitalization burden for HZ is still important in Spain. Data on the current epidemiology are important to evaluate future vaccination strategies.
Collapse
Affiliation(s)
- Marta Corcuera-Munguia
- Department of Medical Specialities and Public Health. Area of Preventive Medicine and Public Health, Rey Juan Carlos University, Madrid, Spain
| | - Ruth Gil-Prieto
- Department of Medical Specialities and Public Health. Area of Preventive Medicine and Public Health, Rey Juan Carlos University, Madrid, Spain
| | - Rafael Garcia-Carretero
- Department of Medical Specialities and Public Health. Area of Internal Medicine, Rey Juan Carlos University, Madrid, Spain
- Mostoles University Hospital, Madrid, Spain
| | - Angel Gil-de-Miguel
- Department of Medical Specialities and Public Health. Area of Preventive Medicine and Public Health, Rey Juan Carlos University, Madrid, Spain
| |
Collapse
|
4
|
Galindo-Utrero A, San-Román-Montero JM, Gil-Prieto R, Gil-de-Miguel Á. Trends in hospitalization and in-hospital mortality rates among patients with lung cancer in Spain between 2010 and 2020. BMC Cancer 2022; 22:1199. [PMID: 36411427 PMCID: PMC9680125 DOI: 10.1186/s12885-022-10205-2] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2022] [Accepted: 10/20/2022] [Indexed: 11/22/2022] Open
Abstract
BACKGROUND Lung cancer is the third most frequent tumor and the main cause of death by tumor in Spain. Although the incidence and mortality are still significantly higher in men than in women, the disparity between the sexes is decreasing. The objective of this study was to analyze the evolution of lung cancer hospitalization and in-hospital mortality rates in Spain from 2010 to 2020. METHODS The reports of the Minimum Basic Data Set (MBDS) at hospital discharge were used to retrospectively analyze the data of all patients with a primary diagnosis of lung cancer, according to the International Classification of Diseases (ICD-9-CM and ICD-10-CM). RESULTS Between 2010 and 2020, there were 315,263 hospitalizations and 70,490 deaths from lung cancer in Spain, the majority (~ 80%) in men. Overall, the rates of hospitalization and in-hospital mortality from lung cancer showed a downward trend throughout the period, although the number of new diagnoses and the absolute number of deaths in women increased. Due to the aging of the population, the degree of comorbidity in patients with lung cancer, although it remains relatively low, is also on the rise. CONCLUSION Lung cancer represents a substantial clinical and economic burden for patients and for the National Health System, so it is necessary to promote primary prevention campaigns, as well as to develop more effective population screening measures to detect cancers early and increase the patient survival.
Collapse
Affiliation(s)
- Abraham Galindo-Utrero
- grid.28479.300000 0001 2206 5938Department of Medical Specialties and Public Health, Area of Preventive Medicine and Public Health, Rey Juan Carlos University, Avenida de Atenas S/N, 28922 Madrid, Spain
| | - Jesús María San-Román-Montero
- grid.28479.300000 0001 2206 5938Department of Medical Specialties and Public Health, Area of Medicine, Rey Juan Carlos University, Avenida de Atenas S/N, 28922 Madrid, Spain
| | - Ruth Gil-Prieto
- grid.28479.300000 0001 2206 5938Department of Medical Specialties and Public Health, Area of Preventive Medicine and Public Health, Rey Juan Carlos University, Avenida de Atenas S/N, 28922 Madrid, Spain
| | - Ángel Gil-de-Miguel
- grid.28479.300000 0001 2206 5938Department of Medical Specialties and Public Health, Area of Preventive Medicine and Public Health, Rey Juan Carlos University, Avenida de Atenas S/N, 28922 Madrid, Spain
| |
Collapse
|
5
|
Chatignoux E, Uhry Z, Grosclaude P, Colonna M, Remontet L. How to produce sound predictions of incidence at a district level using either health care or mortality data in the absence of a national registry: the example of cancer in France. Int J Epidemiol 2021; 50:279-292. [PMID: 33232469 DOI: 10.1093/ije/dyaa217] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/02/2020] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND In many countries, epidemiological surveillance of chronic diseases is monitored by local registries (LR) which do not necessarily cover the whole national territory. This gap has fostered interest in using non-registry databases (e.g., health care or mortality databases) available for the whole territory as proxies for incidence at the local level. However, direct counts from these databases do not provide reliable incidence measures. Accordingly, specific methods are needed to correct proxies and assess their epidemiological usefulness. METHODS This study's objective was to implement a three-stage turnkey methodology using national non-registry data to predict incidence in geographical areas without an LR as follows: constructing a calibration model to make predictions including accurate prediction intervals; accuracy assessment of predictions and rationale for the criteria to assess which predictions were epidemiologically useful; mapping after spatial smoothing of the latter predictions. The methodology was applied to a real-world setting, whereby we aimed to predict cancer incidence, by gender, at the district level in France over the 2007-15 period for 24 different cancer sites, using several health care indicators and mortality. In the present paper, the spatial smoothing performed on predicted incidence of epidemiological interest is illustrated for two examples. RESULTS Predicted incidence of epidemiological interest was possible for 27/34 solid site-gender combinations and for only 2/8 haematological malignancies-gender combinations. Mapping of smoothed predicted incidence provided a clear picture of the main contrasts in incidence between districts. CONCLUSIONS The methodology implemented provides a comprehensive framework to produce valuable predictions of incidence at a district level, using proxy measures and existing LR.
Collapse
Affiliation(s)
- Edouard Chatignoux
- Santé Publique France, French National Public Health Agency, Saint-Maurice, France
| | - Zoé Uhry
- Santé Publique France, French National Public Health Agency, Saint-Maurice, France.,Hospices Civils de Lyon, Service de Biostatistique-Bioinformatique, Pierre-Bénite, Université Lyon 1, France
| | - Pascale Grosclaude
- FRANCIM Network, Toulouse, France.,Tarn Cancer Registry, Claudius Regaud Institute, IUCT-O, Toulouse, France
| | - Marc Colonna
- FRANCIM Network, Toulouse, France.,Isere Cancer Registry, CHU Grenoble-Alpes, Grenoble, France
| | - Laurent Remontet
- Hospices Civils de Lyon, Service de Biostatistique-Bioinformatique, Pierre-Bénite, Université Lyon 1, France.,CNRS; UMR 5558, Laboratoire de Biométrie et Biologie Evolutive, Villeurbanne, France
| |
Collapse
|
6
|
Vicente E, Ruiz de Sabando A, García F, Gastón I, Ardanaz E, Ramos-Arroyo MA. Validation of diagnostic codes and epidemiologic trends of Huntington disease: a population-based study in Navarre, Spain. Orphanet J Rare Dis 2021; 16:77. [PMID: 33568143 PMCID: PMC7877055 DOI: 10.1186/s13023-021-01699-3] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2020] [Accepted: 01/19/2021] [Indexed: 12/29/2022] Open
Abstract
BACKGROUND There is great heterogeneity on geographic and temporary Huntington disease (HD) epidemiological estimates. Most research studies of rare diseases, including HD, use health information systems (HIS) as data sources. This study investigates the validity and accuracy of national and international diagnostic codes for HD in multiple HIS and analyses the epidemiologic trends of HD in the Autonomous Community of Navarre (Spain). METHODS HD cases were ascertained by the Rare Diseases Registry and the reference Medical Genetics Centre of Navarre. Positive predictive values (PPV) and sensitivity with 95% confidence intervals (95% CI) were estimated. Overall and 9-year periods (1991-2017) HD prevalence, incidence and mortality rates were calculated, and trends were assessed by Joinpoint regression. RESULTS Overall PPV and sensitivity of combined HIS were 71.8% (95% CI: 59.7, 81.6) and 82.2% (95% CI: 70.1, 90.4), respectively. Primary care data was a more valuable resource for HD ascertainment than hospital discharge records, with 66% versus 50% sensitivity, respectively. It also had the highest number of "unique to source" cases. Thirty-five per cent of HD patients were identified by a single database and only 4% by all explored sources. Point prevalence was 4.94 (95% CI: 3.23, 6.65) per 100,000 in December 2017, and showed an annual 6.1% increase from 1991 to 1999. Incidence and mortality trends remained stable since 1995-96, with mean annual rates per 100,000 of 0.36 (95% CI: 0.27, 0.47) and 0.23 (95% CI: 0.16, 0.32), respectively. Late-onset HD patients (23.1%), mean age at onset (49.6 years), age at death (66.6 years) and duration of disease (16.7 years) were slightly higher than previously reported. CONCLUSION HD did not experience true temporary variations in prevalence, incidence or mortality over 23 years of post-molecular testing in our population. Ascertainment bias may largely explain the worldwide heterogeneity in results of HD epidemiological estimates. Population-based rare diseases registries are valuable instruments for epidemiological studies on low prevalence genetic diseases, like HD, as long as they include validated data from multiple HIS and genetic/family information.
Collapse
Affiliation(s)
- Esther Vicente
- Community Health Observatory Section, Instituto de Salud Pública y Laboral de Navarra, IdiSNA (Navarre Institute for Health Research), Pamplona, Spain.
- Department of Health Sciences, Universidad Pública de Navarra, IdiSNA, Pamplona, Spain.
| | - Ainara Ruiz de Sabando
- Department of Health Sciences, Universidad Pública de Navarra, IdiSNA, Pamplona, Spain
- Department of Medical Genetics, Complejo Hospitalario de Navarra, IdiSNA, Pamplona, Spain
- Fundación Miguel Servet-Navarrabiomed, IdiSNA, Pamplona, Spain
| | - Fermín García
- Department of Medical Genetics, Complejo Hospitalario de Navarra, IdiSNA, Pamplona, Spain
| | - Itziar Gastón
- Department of Neurology, Complejo Hospitalario de Navarra, IdiSNA, Pamplona, Spain
| | - Eva Ardanaz
- Community Health Observatory Section, Instituto de Salud Pública y Laboral de Navarra, IdiSNA (Navarre Institute for Health Research), Pamplona, Spain
- CIBER of Epidemiology and Public Health (CIBERESP), Madrid, Spain
| | - María A Ramos-Arroyo
- Department of Health Sciences, Universidad Pública de Navarra, IdiSNA, Pamplona, Spain
- Department of Medical Genetics, Complejo Hospitalario de Navarra, IdiSNA, Pamplona, Spain
| |
Collapse
|
7
|
Palmí-Perales F, Gómez-Rubio V, López-Abente G, Ramis R, Sanz-Anquela JM, Fernández-Navarro P. Approximate Bayesian inference for multivariate point pattern analysis in disease mapping. Biom J 2020; 63:632-649. [PMID: 33345346 DOI: 10.1002/bimj.201900396] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2020] [Revised: 08/25/2020] [Accepted: 08/28/2020] [Indexed: 11/08/2022]
Abstract
We present a novel approach for analysing multivariate case-control georeferenced data in a Bayesian disease mapping context using stochastic partial differential equations (SPDEs) and the integrated nested Laplace approximation (INLA) for model fitting. In particular, we propose smooth terms based on SPDE models to estimate the underlying spatial variation as well as risk associated to pollution sources. Log-Gaussian Cox processes are used to estimate the intensity of the cases and controls, to account for risk factors and include a term to measure spatial residual variation. Each intensity is modelled on a baseline spatial effect (estimated from both controls and cases), a disease-specific spatial term and the effects of some covariates. By fitting these models, the residual spatial terms can be easily compared to detect high-risk areas not explained by the covariates. Three different types of effects to model exposure to pollution sources are considered on the distance to the source: a fixed effect, a smooth term to model non-linear effects by means of a discrete random walk of order one and a Gaussian process in one dimension with a Matérn covariance function. Spatial terms are modelled using a Gaussian process in two dimensions with a Matérn covariance function and are approximated using an approach based on solving an SPDE through INLA. Finally, this new framework is applied to a dataset of three different types of cancer and a set of controls from Alcalá de Henares (Madrid, Spain). Covariates available include the distance to several polluting industries and socioeconomic indicators. Our findings point to a possible risk increase due to the proximity to some of these industries.
Collapse
Affiliation(s)
- Francisco Palmí-Perales
- Department of Mathematics, School of Industrial Engineering-Albacete, Universidad de Castilla-La Mancha, Albacete, Spain
| | - Virgilio Gómez-Rubio
- Department of Mathematics, School of Industrial Engineering-Albacete, Universidad de Castilla-La Mancha, Albacete, Spain
| | - Gonzalo López-Abente
- Environmental and Cancer Epidemiology Unit, Carlos III Institute of Health, C/ Sinesio Delgado, Madrid, Spain.,Consortium for Biomedical Research in Epidemiology & Public Health, CIBER Epidemiología y Salud Pública - CIBERESP, Spain
| | - Rebeca Ramis
- Environmental and Cancer Epidemiology Unit, Carlos III Institute of Health, C/ Sinesio Delgado, Madrid, Spain.,Consortium for Biomedical Research in Epidemiology & Public Health, CIBER Epidemiología y Salud Pública - CIBERESP, Spain
| | - José Miguel Sanz-Anquela
- Cancer Registry and Pathology Department, Hospital Universitario Príncipe de Asturias, Campus Universitario, Alcalá de Henares, Madrid, Spain.,Department of Medicine and Medical Specialties, Faculty of Medicine, University of Alcalá de Henares, Campus Universitario, Alcalá de Henares, Madrid, Spain
| | - Pablo Fernández-Navarro
- Environmental and Cancer Epidemiology Unit, Carlos III Institute of Health, C/ Sinesio Delgado, Madrid, Spain.,Consortium for Biomedical Research in Epidemiology & Public Health, CIBER Epidemiología y Salud Pública - CIBERESP, Spain
| |
Collapse
|
8
|
Pagola-Lorz I, Vicente E, Ibáñez B, Torné L, Elizalde-Beiras I, Garcia-Solaesa V, García F, Delfrade J, Jericó I. Epidemiological study and genetic characterization of inherited muscle diseases in a northern Spanish region. Orphanet J Rare Dis 2019; 14:276. [PMID: 31791368 PMCID: PMC6889463 DOI: 10.1186/s13023-019-1227-x] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2019] [Accepted: 10/10/2019] [Indexed: 01/26/2023] Open
Abstract
Background Inherited muscle diseases are a group of rare heterogeneous muscle conditions with great impact on quality of life, for which variable prevalence has previously been reported, probably due to case selection bias. The aim of this study is to estimate the overall and selective prevalence rates of inherited muscle diseases in a northern Spanish region and to describe their demographic and genetic features. Retrospective identification of patients with inherited muscle diseases between 2000 and 2015 from multiple data sources. Demographic and molecular data were registered. Results On January 1, 2016, the overall prevalence of inherited muscle diseases was 59.00/ 100,000 inhabitants (CI 95%; 53.35–65.26). Prevalence was significantly greater in men (67.33/100,000) in comparison to women (50.80/100,000) (p = 0.006). The highest value was seen in the age range between 45 and 54 (91.32/100,000) years. Myotonic dystrophy type 1 was the most common condition (35.90/100,000), followed by facioscapulohumeral muscular dystrophy (5.15/100,000) and limb-girdle muscular dystrophy type 2A (2.5/100,000). Conclusions Prevalence of inherited muscle diseases in Navarre is high in comparison with the data reported for other geographical regions. Standard procedures and analyses of multiple data sources are needed for epidemiological studies of this heterogeneous group of diseases.
Collapse
Affiliation(s)
- Inmaculada Pagola-Lorz
- Department of Neurology, Complejo Hospitalario de Navarra, IdiSNA (Navarre Institute for Health Research), Pamplona, Spain
| | - Esther Vicente
- Community Health Observatory Section, Instituto de Salud Pública y Laboral de Navarra, IdiSNA, Pamplona, Spain.,Department of Health Sciences, Universidad Pública de Navarra (UPNA), IdiSNA, Pamplona, Spain
| | - Berta Ibáñez
- Methodology Unit. Navarrabiomed, Universidad Pública de Navarra (UPNA), IdiSNA, Pamplona, Spain
| | - Laura Torné
- Department of Neurology, Complejo Hospitalario de Navarra, IdiSNA (Navarre Institute for Health Research), Pamplona, Spain
| | - Itsaso Elizalde-Beiras
- Primary Care, Servicio Navarro de Salud - Osasunbidea, IdiSNA, Pamplona, Spain.,Miguel Servet Foundation, Navarrabiomed, Pamplona, Spain
| | - Virginia Garcia-Solaesa
- Department of Neurology, Complejo Hospitalario de Navarra, IdiSNA (Navarre Institute for Health Research), Pamplona, Spain.,Department of Genetics, Complejo Hospitalario de Navarra, IdiSNA, Pamplona, Spain
| | - Fermín García
- Department of Genetics, Complejo Hospitalario de Navarra, IdiSNA, Pamplona, Spain
| | - Josu Delfrade
- Community Health Observatory Section, Instituto de Salud Pública y Laboral de Navarra, IdiSNA, Pamplona, Spain.,CIBER Epidemiology and Public Health (CIBERESP), Madrid, Spain
| | - Ivonne Jericó
- Department of Neurology, Complejo Hospitalario de Navarra, IdiSNA (Navarre Institute for Health Research), Pamplona, Spain. .,Department of Neurology, Complejo Hospitalario de Navarra, 31008, Pamplona, C/ Irunlarrea, Spain.
| |
Collapse
|
9
|
Escribà JM, Banqué M, Macià F, Gálvez J, Esteban L, Pareja L, Clèries R, Sanz X, Castells X, Borrás JM, Ribes J. Detection of incident breast and colorectal cancer cases from an administrative healthcare database in Catalonia, Spain. Clin Transl Oncol 2019; 22:943-952. [PMID: 31586294 DOI: 10.1007/s12094-019-02219-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2019] [Accepted: 09/24/2019] [Indexed: 10/25/2022]
Abstract
OBJECTIVE To validate the Catalan minimum basic data set (MBDS) of hospital discharges as an information source for detecting incident breast (BC) and colorectal cancer (CRC), against the Hospital del Mar Cancer Registry (RTHMar) in Barcelona (Spain) as the gold standard. METHODS Using ASEDAT software (Analysis, Selection and Extraction of Tumour Data), we identified Catalan public hospital discharge abstracts in patients with a first-time diagnosis of BC and CRC in the years 2005, 2008, and 2011, aggregated by unique patient identifiers and sorted by date. Once merged with the RTHMar database and anonymized, tumour-specific algorithms were validated to extract data on incident cases, tumour stage, surgical treatment, and date of incidence. RESULTS MBDS had a respective sensitivity and positive predictive value (PPV) of 78.0% (564/723) and 90.5% (564/623) for BC case detection; and 83.9% (387/461) and 94.9% (387/408) for CRC case detection. The staging algorithms overestimated the proportion of local-stage cases and underestimated the regional-stage cases in both cancers. When loco-regional stage and surgery were combined, sensitivity and PPV reached 98.3% and 99.8%, respectively, for BC and 96.4% and 98.4% for CRC. The differences between dates of incidence between RTHMar and MBDS were greater for BC cases without initial surgery, whereas they were generally smaller and homogeneous for CRC cases. CONCLUSIONS The MBDS is a valid and efficient instrument to improve the completeness of a hospital-based cancer registry (HBCR), particularly in BC and CRC, which require hospitalization and are predominantly surgical.
Collapse
Affiliation(s)
- J M Escribà
- Catalan Cancer Registry, Cancer Planning Directorate, Department of Health, Generalitat de Catalunya, Av. Gran Via 199-203, 1st floor, 08908, L' Hospitalet de Llobregat, Spain. .,Department of Clinical Sciences, University of Barcelona, Campus de Bellvitge, Feixa Llarga s/n, 08907, L' Hospitalet de Llobregat, Barcelona, Spain.
| | - M Banqué
- Unit of Prevention and Cancer Registry, Service of Epidemiology and Evaluation, Parc de Salut Mar, Barcelona, Passeig Marítim 25-29, 08003, Barcelona, Spain.,Anoia Health Consortium, Av. Catalunya 11, 08700, Igualada, Barcelona, Spain
| | - F Macià
- Unit of Prevention and Cancer Registry, Service of Epidemiology and Evaluation, Parc de Salut Mar, Barcelona, Passeig Marítim 25-29, 08003, Barcelona, Spain
| | - J Gálvez
- Catalan Cancer Registry, Cancer Planning Directorate, Department of Health, Generalitat de Catalunya, Av. Gran Via 199-203, 1st floor, 08908, L' Hospitalet de Llobregat, Spain
| | - L Esteban
- Catalan Cancer Registry, Cancer Planning Directorate, Department of Health, Generalitat de Catalunya, Av. Gran Via 199-203, 1st floor, 08908, L' Hospitalet de Llobregat, Spain
| | - L Pareja
- Catalan Cancer Registry, Cancer Planning Directorate, Department of Health, Generalitat de Catalunya, Av. Gran Via 199-203, 1st floor, 08908, L' Hospitalet de Llobregat, Spain
| | - R Clèries
- Catalan Cancer Registry, Cancer Planning Directorate, Department of Health, Generalitat de Catalunya, Av. Gran Via 199-203, 1st floor, 08908, L' Hospitalet de Llobregat, Spain.,Department of Clinical Sciences, University of Barcelona, Campus de Bellvitge, Feixa Llarga s/n, 08907, L' Hospitalet de Llobregat, Barcelona, Spain
| | - X Sanz
- Catalan Cancer Registry, Cancer Planning Directorate, Department of Health, Generalitat de Catalunya, Av. Gran Via 199-203, 1st floor, 08908, L' Hospitalet de Llobregat, Spain
| | - X Castells
- Unit of Prevention and Cancer Registry, Service of Epidemiology and Evaluation, Parc de Salut Mar, Barcelona, Passeig Marítim 25-29, 08003, Barcelona, Spain.,Faculty of Medicine, Universitat Autònoma de Barcelona, Cerdanyola del Vallès, 08193, Bellaterra, Spain
| | - J M Borrás
- Catalan Cancer Registry, Cancer Planning Directorate, Department of Health, Generalitat de Catalunya, Av. Gran Via 199-203, 1st floor, 08908, L' Hospitalet de Llobregat, Spain.,Department of Clinical Sciences, University of Barcelona, Campus de Bellvitge, Feixa Llarga s/n, 08907, L' Hospitalet de Llobregat, Barcelona, Spain
| | - J Ribes
- Catalan Cancer Registry, Cancer Planning Directorate, Department of Health, Generalitat de Catalunya, Av. Gran Via 199-203, 1st floor, 08908, L' Hospitalet de Llobregat, Spain.,Department of Clinical Sciences, University of Barcelona, Campus de Bellvitge, Feixa Llarga s/n, 08907, L' Hospitalet de Llobregat, Barcelona, Spain
| |
Collapse
|
10
|
Peeters LM, van Munster CE, Van Wijmeersch B, Bruyndonckx R, Lamers I, Hellings N, Popescu V, Thalheim C, Feys P. Multidisciplinary data infrastructures in multiple sclerosis: Why they are needed and can be done! Mult Scler 2018; 25:500-509. [PMID: 30381984 DOI: 10.1177/1352458518807076] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
Personalized treatment is highly desirable in multiple sclerosis (MS). We believe that multidisciplinary measurements including clinical, functional and patient-reported outcome measures in combination with extensive patient profiling can enhance personalized treatment and rehabilitation strategies. We elaborate on four reasons behind this statement: (1) MS disease activity and progression are complex and multidimensional concepts in nature and thereby defy a one-size-fits-all description, (2) functioning, progression, treatment, and rehabilitation effects are interdependent and should be investigated together, (3) personalized healthcare is based on the dynamics of system biology and on technology that confirms a patient's fundamental biology and (4) inclusion of patient-reported outcome measures can facilitate patient-relevant healthcare. We discuss currently available multidisciplinary MS data initiatives and introduce joint actions to further increase the overall success. With this topical review, we hope to drive the MS community to invest in expanding towards more multidisciplinary and longitudinal data collection.
Collapse
Affiliation(s)
| | | | - Bart Van Wijmeersch
- Department of Neurology, Biomedical Research Institute, Hasselt University, Hasselt, Belgium/Rehabilitation & MS Center, Overpelt, Belgium
| | - Robin Bruyndonckx
- Interuniversity Institute for Biostatistics and statistical Bioinformatics, Hasselt University, Hasselt, Belgium/Laboratory of Medical Microbiology, Vaccine & Infectious Diseases Institute, University of Antwerp, Antwerp, Belgium
| | - Ilse Lamers
- Department of Neurology, Biomedical Research Institute, Hasselt University, Hasselt, Belgium/Rehabilitation & MS Center, Overpelt, Belgium
| | - Niels Hellings
- Biomedical Research Institute, Hasselt University, Hasselt, Belgium
| | - Veronica Popescu
- Department of Neurology, Biomedical Research Institute, Hasselt University, Hasselt, Belgium/Rehabilitation & MS Center, Overpelt, Belgium
| | - Christoph Thalheim
- External Affairs, European Multiple Sclerosis Platform, Brussels, Belgium
| | - Peter Feys
- Biomedical Research Institute, Hasselt University, Hasselt, Belgium
| |
Collapse
|
11
|
Gil-Borrelli CC, Latasa Zamalloa P, Martín Ríos MD, Rodríguez Arenas MÁ. [Interpersonal violence in Spain through national hospital discharge survey]. GACETA SANITARIA 2018; 33:317-324. [PMID: 29866371 DOI: 10.1016/j.gaceta.2018.02.008] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/27/2017] [Revised: 02/11/2018] [Accepted: 02/13/2018] [Indexed: 11/25/2022]
Abstract
OBJECTIVE To describe the epidemiology of interpersonal violence in Spain. METHOD Descriptive study of the cases of patients with secondary diagnosis of aggression registered on a national hospital discharge database, between 1999 and 2011, using the codes from E960 to E969 of the ICD-9. The distribution by sex, age and type of discharge, associated morbidity, mortality and by autonomous community is described. The quality of the record is studied according to its temporal variation. RESULTS The case profile of aggression in men (85%) is of a patient between 15 and 44 years old, who in 93.7% of cases requires urgent care and whose severity is moderate (95% discharge home). Two point five percent of patients are readmitted and death occurs in1.1%. The profile in women (15%) differs slightly, with an age between 31 and 52 years, 94% require urgent attention, although 96% have moderate severity; 3% are readmitted and 1.7% die. CONCLUSIONS Although they need to be improved to avoid certain limitations, health information systems are a rich source of data that can be used for research in health and, through their results, for the development of prevention plans and intervention in matters of violence.
Collapse
Affiliation(s)
- Christian Carlo Gil-Borrelli
- Escuela Nacional de Sanidad, Instituto de Salud Carlos III, Madrid, España; Grupo de Investigación SIVIVO, España.
| | - Pello Latasa Zamalloa
- Grupo de Investigación SIVIVO, España; Servicio de Epidemiología, Consejería de Sanidad de la Comunidad de Madrid, Madrid, España
| | - María Dolores Martín Ríos
- Grupo de Investigación SIVIVO, España; Servicio de Medicina Preventiva y Salud Pública, Hospital Universitario Fundación Jiménez Díaz, Madrid, España
| | - M Ángeles Rodríguez Arenas
- Escuela Nacional de Sanidad, Instituto de Salud Carlos III, Madrid, España; Grupo de Investigación SIVIVO, España
| |
Collapse
|
12
|
García-de Cruz S, Aldea-Mansilla C, Campos Bueno Á, del Villar Sordo V. Fiabilidad del conjunto mínimo básico de datos como herramienta epidemiológica de la enfermedad tuberculosa. Arch Bronconeumol 2018; 54:107-108. [DOI: 10.1016/j.arbres.2017.07.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2017] [Revised: 06/26/2017] [Accepted: 07/16/2017] [Indexed: 11/30/2022]
|